Eli Lilly Management

Management criteria checks 2/4

Eli Lilly's CEO is Dave Ricks, appointed in Jan 2017, has a tenure of 9.42 years. total yearly compensation is $36.70M, comprised of 4.6% salary and 95.4% bonuses, including company stock and options. directly owns 0.091% of the company’s shares, worth CHF693.19M. The average tenure of the management team and the board of directors is 6.8 years and 10 years respectively.

Key information

Dave Ricks

Chief executive officer

US$36.7m

Total compensation

CEO salary percentage	4.63%
CEO tenure	9.4yrs
CEO ownership	0.09%
Management average tenure	6.8yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Ricks's remuneration changed compared to Eli Lilly's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2026	n/a	n/a	US$25b
Dec 31 2025	US$37m	US$2m	US$21b
Sep 30 2025	n/a	n/a	US$18b
Jun 30 2025	n/a	n/a	US$14b
Mar 31 2025	n/a	n/a	US$11b
Dec 31 2024	US$29m	US$2m	US$11b
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b

Compensation vs Market: Dave's total compensation ($USD36.70M) is above average for companies of similar size in the Swiss market ($USD6.16M).

Compensation vs Earnings: Dave's compensation has increased by more than 20% in the past year.

CEO

Dave Ricks (58 yo)

9.4yrs

Tenure

US$36,698,337

Compensation

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman & CEO	9.4yrs	US$36.70m	0.091% CHF 693.2m
Lucas Montarce	Executive VP & CFO	1.8yrs	US$8.48m	0.0018% CHF 13.8m
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories	8yrs	US$17.79m	0.026% CHF 200.3m
Anat Hakim	Executive VP	6.3yrs	US$9.85m	0.0062% CHF 47.2m
Jacob Van Naarden	Executive VP	no data	US$7.59m	0.0041% CHF 30.9m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	13.6yrs	no data	0.00059% CHF 4.5m
Diogo Rau	Executive VP and Chief Information & Digital Officer	5.1yrs	US$5.10m	0.0030% CHF 22.4m
Michael Czapar	Director of Investor Relations	7.6yrs	no data	no data
Eric Dozier	Executive VP & Chief People Officer	3.5yrs	no data	0.0017% CHF 12.6m
Ilya Yuffa	Executive VP and President of Lilly USA & Global Customer Capabilities	5.7yrs	no data	0.0036% CHF 27.4m
Patrik Jonsson	Executive VP & President of Lilly International	6.8yrs	US$3.92m	0.0069% CHF 52.1m
Frank Cunningham	Senior Vice President of Global Value & Access	6.8yrs	no data	no data

6.8yrs

Average Tenure

52yo

Average Age

Experienced Management: LLY's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Ricks	Chairman & CEO	9.4yrs	US$36.70m	0.091% CHF 693.2m
Gabrielle Sulzberger	Independent Director	5.4yrs	US$365.50k	0.00033% CHF 2.5m
Sidney Taurel	Chairman Emeritus	17.4yrs	US$13.06m	no data
Jon Erik Fyrwald	Independent Director	20.6yrs	US$343.80k	0.00019% CHF 1.4m
Ralph Alvarez	Independent Director	17.2yrs	US$361.00k	0.000090% CHF 682.2k
Carolyn Bertozzi	Independent Director	less than a year	US$7.68k	0.00022% CHF 1.7m
William Kaelin	Independent Director	14yrs	US$392.00k	no data
Mary Hedley	Independent Director	4.1yrs	US$339.00k	0.000040% CHF 303.2k
Juan Luciano	Lead Independent Director	10.3yrs	US$398.00k	0.0019% CHF 14.3m
Katherine Baicker	Independent Director	14.5yrs	US$361.00k	no data
Jamere Jackson	Independent Director	9.7yrs	US$368.00k	0.000020% CHF 151.6k
Kimberly Johnson	Independent Director	5.3yrs	US$336.00k	no data

10.0yrs

Average Tenure

64.5yo

Average Age

Experienced Board: LLY's board of directors are seasoned and experienced ( 10 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/02 07:24
End of Day Share Price	2026/06/02 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Emily Field	Barclays
Kerry Holford	Berenberg

Eli Lilly Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Eli Lilly And Company Announces Results From Phase 3 LIBRETTO-432 Clinical Trial Of Retevmo (Selpercatinib) As Adjuvant Therapy Versus Placebo In Patients With Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer

Eli Lilly and Company Presents New Data on Foundayo, Mounjaro and Retatrutide At the American Diabetes Association's 86Th Scientific Sessions

Eli Lilly and Company Announces Expanded Coverage for Foundayo and Zepbound Obesity Medicines

Eli Lilly and Company (NYSE:LLY) entered into an agreement to acquire Curevo, Inc. from HBM Healthcare Investments AG (SWX:HBMN), a fund managed by HBM Partners Ltd., and others for $1.5 billion.

Eli Lilly and Company Showcases Oncology Portfolio Across Tumor Types and Treatment Modalities At the American Society of Clinical Oncology Annual Meeting

Eli Lilly and Company Announces Results of Retatrutide Phase 3 Clinical Trial

Walden Macht Haran & Williams LLP Secures Victory Against Eli Lilly and Company

Insufficient new directors

Eli Lilly and Company Presents Results for Foundayo and Zepbound in Weight Loss Maintenance Trials

First quarter dividend of US$1.73 announced

Eli Lilly and Company Announces Omvoh Demonstrates Durable Disease Clearance in Ulcerative Colitis Through Four Years

Eli Lilly and Company Raises Earning Guidance for the Year 2026

First quarter 2026 earnings released: EPS: US$8.26 (vs US$3.07 in 1Q 2025)

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire remaining majority stake in Ajax Therapeutics, Inc. for $2.3 billion.

Insufficient new directors

Lilly Reportedly in Advanced Talks to Acquire Kelonia Therapeutics for over $2 Billion

Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk

Eli Lilly And Company Announces Positive Phase 3 Results For Jaypirca (Pirtobrutinib) In Previously Treated CLL/SLL

Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S

Eli Lilly And Company Receives FDA Approval For Foundayo (Orforglipron) For Weight Loss

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Centessa Pharmaceuticals plc (NasdaqGS:CNTA) from Medicxi Ventures (UK) LLP, Index Ventures SA, General Atlantic Service Company, L.P. and other shareholders for $5.6 billion.

Eli Lilly and Company Presents Phase 3B Data on Taltz and Zepbound Combination for Adults with Psoriatic Arthritis and Obesity

Eli Lilly And Company Delivers Durable Disease Control With Ebglyss For Moderate-To-Severe Atopic Dermatitis

Eli Lilly And Company Demonstrates Significant Reductions In A1C And Weight With Retatrutide In First Phase 3 Trial For Treatment Of Type 2 Diabetes

Eli Lilly And Company Announces Positive Phase 3 Results For EBGLYSS In Pediatric Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company, Annual General Meeting, May 04, 2026

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options

Insufficient new directors

Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata

Eli Lilly and Company Announces Detailed Results from ACHIEVE-3

Eli Lilly and Company Announces the U.S. Food and Drug Administration Approves a Label Expansion for Zepbound® (tirzepatide)

Eli Lilly and Company Presents New Long-Term Data from Eli Lilly and Company's Omvoh (mirikizumab-mrkz)

Eli Lilly and Company Announces Positive Topline Results from Taltz (Ixekizumab) and Zepbound (Tirzepatide)

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 LIBRETTO-432 Clinical Trial of Retevmo

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Orna Therapeutics, Inc. in a transaction valued at $2.4 billion.

Upcoming dividend of US$1.73 per share

Full year 2025 earnings released: EPS: US$22.95 (vs US$11.76 in FY 2024)

Eli Lilly and Company Provides Earnings Guidance for the Full Year 2026

Third quarter dividend of US$1.73 announced

Insufficient new directors

Eli Lilly and Company to Report Q4, 2025 Results on Feb 04, 2026

Eli Lilly and Company's Sofetabart Mipitecan Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Certain Patients with Platinum-Resistant Ovarian Cancer

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Eli Lilly and Company Announces Positive Topline Results from the Novel TOGETHER-PsA Open-Label Phase 3b Trial Evaluating the Concomitant Use of Taltz (Tirzepatide)

Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.

Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli Lilly

Third quarter dividend of US$1.73 announced

Insufficient new directors

Celltrion, Inc. (KOSE:A068270) acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).

Eli Lilly and Company Announces Oral GLP-1 Orforglipron

Eli Lilly and Company Announces Positive Topline Results from the ATTAIN-MAINTAIN trial

Third quarter dividend of US$1.73 announced

Eli Lilly and Company Announces Updated Data for Lilly's Inluriyo™ (Imlunestrant) Reinforce Efficacy Results as Monotherapy and in Combination with Verzenio® (Abemaciclib) in Er+, Her2- Advanced Breast Cancer

Eli Lilly and Company Announces Positive Topline Results from the Phase 3 TRIUMPH-4 Clinical Trial

Insufficient new directors

Eli Lilly and Company Announces Results from the Phase 3 Bruin CLL-313 Clinical Trial of Jaypirca (Pirtobrutinib)

Eli Lilly and Company Announces U.S. Food and Drug Administration Approves Expanded Indication for Lilly's Jaypirca (Pirtobrutinib, 100 Mg & 50 Mg Tablets)

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Eli Lilly and Company to Present Data from Two Positive Phase 3 Studies of Jaypirca (Pirtobrutinib) in Chronic Lymphocytic Leukemia at the 2025 American Society of Hematology Annual Meeting

Now 20% undervalued

Eli Lilly and Company Announces Appointment of Carolyn R. Bertozzi, Ph.D as New Board Member and Member of Science and Technology Committee and the Ethics and Compliance Committee, Effective December 8, 2025

Eli Lilly and Company Announces Management Appointments

Eli Lilly and Company Announces Positive Results from A Phase 2 Trial Evaluating the Safety and Efficacy of Eloralintide

Third quarter dividend of US$1.50 announced

Third quarter 2025 earnings released: EPS: US$6.21 (vs US$1.08 in 3Q 2024)

Investor sentiment improves as stock rises 22%

Eli Lilly and Company Raises Earnings Guidance for the Year 2025

Lilly's Omvoh (mirikizumab-mrkz) Approves by U.S. FDA as a Single-Injection Maintenance Regimen in Adults with Ulcerative Colitis